Efficacy of Carbapenems Compared With Noncarbapenem Broad-Spectrum Beta-Lactam Antibiotics as Initial Antibiotic Therapy Against Sepsis: A Nationwide Observational Study.
Journal
Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
18
8
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
ppublish
Résumé
As causative pathogens are not usually identified at the time of initiating antibiotics in sepsis, carbapenems are commonly used as an initial treatment. To reduce indiscriminate use of carbapenems, the efficacy of alternative empiric regimens, such as piperacillin-tazobactam and the fourth-generation cephalosporins, should be elucidated. This study aimed to evaluate survival effect associated with carbapenems as initial therapy for sepsis compared with these antibiotics. Multicenter retrospective observational study. Tertiary hospitals in Japan. Adult patients diagnosed as having sepsis from 2006 to 2019. Administration of carbapenems as initial antibiotic therapy. This study used data of adult patients with sepsis extracted from a large-scale database in Japan. Patients were divided into two groups as follows: patients receiving carbapenems and patients receiving noncarbapenem broad-spectrum beta-lactam antibiotics as initial treatment. In-hospital mortality was compared between the groups by a logistic regression model adjusted by an inverse probability treatment weighting using propensity scores. To evaluate heterogeneity of effects according to patient characteristics, we also fitted logistic models in several subgroups. Among 7,392 patients with sepsis, 3,547 patients received carbapenems, and 3,845 patients received noncarbapenem agents. The logistic model showed no significant association between carbapenem therapy and lower mortality (adjusted OR 0.88, p = 0.108). Subgroup analyses suggested that there were significant survival benefits associated with carbapenem therapy in patients with septic shock, in ICUs, or with mechanical ventilation ( p for effect modifications: < 0.001, 0.014, and 0.105, respectively). Compared with the noncarbapenem broad-spectrum antibiotics, carbapenems as an initial therapy for sepsis were not associated with significantly lower mortality.
Identifiants
pubmed: 37232855
doi: 10.1097/CCM.0000000000005932
pii: 00003246-202309000-00012
pmc: PMC10426781
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Monobactams
0
Piperacillin, Tazobactam Drug Combination
157044-21-8
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1210-1221Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have disclosed that they do not have any potential conflicts of interest.
Références
Singer M, Deutschman CS, Seymour CW, et al.: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315:801–810
Fleischmann-Struzek C, Mellhammar L, Rose N, et al.: Incidence and mortality of hospital- and ICU-treated sepsis: Results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020; 46:1552–1562
Rudd KE, Johnson SC, Agesa KM, et al.: Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the global burden of disease study. Lancet. 2020; 395:200–211
Ibrahim EH, Sherman G, Ward S, et al.: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2020; 118:146–155
Barie PS, Hydo LJ, Shou J, et al.: Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect (Larchmt). 2005; 6:41–54
Kumar A, Roberts D, Wood KE, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34:1589–1596
Kumar A, Ellis P, Arabi Y, et al.; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group: Initiation of inappropriate antimicrobial therapy results in a five-fold reduction of survival in human septic shock. Chest. 2009; 136:1237–1248
Paul M, Shani V, Muchtar E, et al.: Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010; 54:4851–4863
Ferrer R, Martin-Loeches I, Phillips G, et al.: Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: Results from a guideline-based performance improvement program. Crit Care Med. 2014; 42:1749–1755
Rhodes A, Evans LE, Alhazzani W, et al.: Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017; 43:304–377
Evans L, Rhodes A, Alhazzani W, et al.: Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021; 47:1181–1247
Dulhunty JM, Paterson DL, Webb SAR, et al.: Antimicrobial utilization in 37 Australian and New Zealand intensive care units. Anaesth Intensive Care. 2011; 39:231–237
Paterson DL, Ko WC, Von Gottberg A, et al.: Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004; 39:31–37
Perez F, Bonomo RA: Can we really use β-lactam/β-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum β-lactamase-producing bacteria? Clin Infect Dis. 2012; 54:175–177
Abe T, Ogura H, Shiraishi A, et al.; JAAM FORECAST group: Characteristics, management, and in-hospital mortality among patients with severe sepsis in intensive care units in Japan: The FORECAST study. Crit Care. 2018; 22:322
Rhodes NJ, Wagner JL, Davis SL, et al.; MAD-ID Research Network: Trends in and predictors of carbapenem consumption across North American hospitals: Results from a multicenter survey by the MAD-ID research network. Antimicrob Agents Chemother. 2019; 63:e00327–e00319
European Surveillance of Antimicrobial Consumption Network: Antimicrobial consumption in the EU/EEA (ESAC-Net)—Annual epidemiological report for 2021. Available at: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-consumption-europe-2021 . Accessed December 21, 2022
Hussein K, Sprecher H, Mashiach T, et al.: Carbapenem resistance among Klebsiella pneumoniae isolates: Risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol. 2009; 30:666–671
Patel G, Huprikar S, Factor SH, et al.: Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008; 29:1099–1106
Benanti GE, Brown ART, Shigle TL, et al.: Carbapenem versus cefepime or piperacillin-tazobactam for empiric treatment of bacteremia due to extended-spectrum-beta-lactamase-producing Escherichia coli in patients with hematologic malignancy. Antimicrob Agents Chemother. 2019; 63:e01813–e01818
Chang YY, Yang YS, Wu SL, et al.; ACTION Study Group: Comparison of cefepime-cefpirome and carbapenem therapy for Acinetobacter bloodstream infection in a multicenter study. Antimicrob Agents Chemother. 2020; 64:e02392–e02319
Palacios-Baena ZR, Gutiérrez-Gutiérrez B, Calbo E, et al.; Spanish Network for Research in Infectious Diseases (REIPI)/European Study Group of Bloodstream Infections and Sepsis (ESGBIS)/INCREMENT Group: Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: Results from the INCREMENT cohort. Clin Infect Dis. 2017; 65:1615–1623
Vardakas KZ, Tansarli GS, Rafailidis PI, et al.: Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: A systematic review and meta-analysis. J Antimicrob Chemother. 2012; 67:2793–2803
Tashiro M, Obata Y, Takazono T, et al.: Association between fluid infusions and the recovery from acute kidney injury in patients administered liposomal amphotericin B: A nationwide observational study. Ren Fail. 2022; 44:282–292
Angus DC, Linde-Zwirble WT, Lidicker J, et al.: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29:1303–1310
Wilhelms SB, Huss FR, Granath G, et al.: Assessment of incidence of severe sepsis in Sweden using different ways of abstracting International Classification of Diseases codes: Difficulties with methods and interpretation of results. Crit Care Med. 2010; 38:1442–1449
Liu B, Hadzi-Tosev M, Liu Y, et al.: Accuracy of International Classification of Diseases, 10th revision codes for identifying sepsis: A systematic review and meta-analysis. Crit Care Explor. 2022; 4:e0788
Kollef MH, Morrow LE, Niederman MS, et al.: Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006; 129:1210–1218
Leone M, Bechis C, Baumstarck K, et al.; AZUREA Network Investigators: De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: A multicenter non-blinded randomized noninferiority trial. Intensive Care Med. 2014; 40:1399–1408
Charlson ME, Pompei P, Ales KL, et al.: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987; 40:373–383
Quan H, Sundararajan V, Halfon P, et al.: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43:1130–1139
Kidney Disease: Improving global outcomes (KDIGO) acute kidney injury work group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2012; 2:1–138
Jones G, Taright N, Boelle PY, et al.: Accuracy of ICD-10 codes for surveillance of Clostridium difficile infections, France. Emerg Infect Dis. 2012; 18:979–981
Gayat E, Pirracchio R, Resche-Rigon M, et al.: Propensity scores in intensive care and anaesthesiology literature: A systematic review. Intensive Care Med. 2012; 36:1993–2003
D’Agostino RB Jr, D’Agostino RB Sr: Estimating treatment effects using observational data. JAMA. 2007; 297:314–316
Feng M, McSparron JI, Kien DT, et al.: Transthoracic echocardiography and mortality in sepsis: Analysis of the MIMIC-III database. Intensive Care Med. 2018; 44:884–892
Allan V, Ramagopalan SV, Mardekian J, et al.: Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J Comp Eff Res. 2020; 9:603–614
Cheng L, Nelson BC, Mehta M, et al.: Piperacillin-tazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2017; 61:e00276–e00217
Barradell LB, Bryson HM: Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994; 47:471–505
Woerther PL, Burdet C, Chachaty E, et al.: Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: Toward the globalization of CTX-M. Clin Microbiol Rev. 2013; 26:744–758
Vardakas KZ, Tansarli GS, Rafailidis PI, et al.: Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: A systematic review and meta-analysis. J Antimicrob Chemother. 2012; 67:2793–2803
Tamma PD, Han JH, Rock C, et al.; Antibacterial Resistance Leadership Group: Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis. 2015; 60:1319–1325
Lee NY, Lee CC, Huang WH, et al.: Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis. 2013; 56:488–495
Nakama R, Shingaki A, Miyazato H, et al.: Current status of extended spectrum β-lactamase-producing Escherichia coli , Klebsiella pneumoniae and Proteus mirabilis in Okinawa prefecture, Japan. J Infect Chemother. 2016; 22:281–286
Capsoni N, Bellone P, Aliberti S, et al.: Prevalence, risk factors and outcomes of patients coming from the community with sepsis due to multidrug resistant bacteria. Multidiscip Respir Med. 2019; 14:23
Seymour CW, Gesten F, Prescott HC, et al.: Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med. 2017; 376:2235–2244
Teng C, Reveles KR, Obodozie-Ofoegbu OO, et al.: Clostridium difficile infection risk with important antibiotic classes: An analysis of the FDA adverse event reporting system. Int J Med Sci. 2019; 16:630–635
van Loon K, Voor In ‘t Holt AF, Vos MC: A systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017; 62:e01730–e01717
World Health Organization: Antimicrobial resistance: Global report on surveillance. World Health Organization, 2014. Available at: https://apps.who.int/iris/handle/10665/112642 . Accessed April 31, 2022
Nathwani D, Raman G, Sulham K, et al.: Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: A systematic review and meta-analysis. Antimicrob Resist Infect Contr. 2014; 3:32
Kirikae T, Mizuguchi Y, Arakawa Y: Investigation of isolation rates of Pseudomonas aeruginosa with and without multidrug resistance in medical facilities and clinical laboratories in Japan. J Antimicrob Chemother. 2008; 61:612–615
Bad Bugs, No Drugs, as Antibiotic Discovery Stagnates … A Public Health Crisis Brews: Available at: https://www.idsociety.org/globalassets/idsa/policy--advocacy/current_topics_and_issues/antimicrobial_resistance/10x20/statements/070104-as-antibiotic-discovery-stagnates-a-public-health-crisis-brews.pdf . Accessed April 18, 2022
Kalil AC, Metersky ML, Klompas M, et al.: Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63:e61–e111